AXSM

Axsome Therapeutics, Inc. is a New York-based biopharmaceutical company specializing in the development of innovative therapies targeting central nervous system (CNS) disorders. The company’s diverse pipeline includes candidates for conditions such as major depressive disorder, migraine, and chronic pain, addressing critical unmet medical needs in a substantial market. With a strong emphasis on scientific rigor and patient-centric solutions, Axsome is well-positioned to lead advancements in mental health treatment, presenting a compelling investment opportunity for institutional investors seeking exposure to breakthrough therapies in the biopharmaceutical sector.